Sign In
Buy SIBN
$15.82
-0.0200 (-0.126%)
At Close: Jun 22, 2026
Earnings Preview: Si-Bone (SIBN) Q1 Earnings Expected to Decline
04:33pm, Monday, 02'nd May 2022
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SI-BONE To Present at BofA Securities 2022 Healthcare Conference
08:03pm, Monday, 18'th Apr 2022 GlobeNewswire Inc.
SANTA CLARA, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announ
SI-BONE To Present at BofA Securities 2022 Healthcare Conference
04:03pm, Monday, 18'th Apr 2022
SANTA CLARA, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announce
SI-BONE, Inc. (SIBN) CEO Laura Francis on Q4 2021 Results - Earnings Call Transcript
03:53am, Tuesday, 01'st Mar 2022 Seeking AlphaSI-BONE, Inc. (SIBN) CEO Laura Francis On Q4 2021 Results - Earnings Call Transcript
10:53pm, Monday, 28'th Feb 2022
SI-BONE, Inc. (SIBN) CEO Laura Francis On Q4 2021 Results - Earnings Call Transcript
SI-BONE GAAP EPS of -$0.43 misses by $0.05, revenue of $25.2M beats by $0.39M
09:06pm, Monday, 28'th Feb 2022 Seeking Alpha
SI-BONE press release (SIBN): Q4 GAAP EPS of -$0.43 misses by $0.05.Revenue of $25.2M (+13.8% Y/Y) beats by $0.39M.
SI-BONE, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Issues 2022 Revenue Guidance
09:02pm, Monday, 28'th Feb 2022 GlobeNewswire Inc.
SANTA CLARA, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported
SI-BONE, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Issues 2022 Revenue Guidance
09:02pm, Monday, 28'th Feb 2022 GlobeNewswire
SANTA CLARA, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter and full year ended December 31, 2021.
SI-BONE To Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
01:00pm, Tuesday, 01'st Feb 2022 GlobeNewswire Inc.
SANTA CLARA, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announc
SI-BONE (SIBN) Investor Presentation - Slideshow
07:50pm, Friday, 21'st Jan 2022 Seeking Alpha
SI-BONE to participate in 24th Annual Needham Virtual Growth Conference
09:03pm, Monday, 27'th Dec 2021 GlobeNewswire Inc.
SANTA CLARA, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic
SI-BONE (NASDAQ:SIBN) Given New $30.00 Price Target at Truist Securities
08:06am, Friday, 24'th Dec 2021 Transcript Daily
SI-BONE (NASDAQ:SIBN) had its price objective reduced by Truist Securities from $35.00 to $30.00 in a research report report published on Tuesday morning, Analyst Ratings Network reports. They currently have a buy rating on the stock. Several other research firms have also weighed in on SIBN. Needham & Company LLC restated a buy rating and []
Equities Analysts Set Expectations for SI-BONE, Inc.s FY2023 Earnings (NASDAQ:SIBN)
01:32pm, Thursday, 23'rd Dec 2021 Dakota Financial News
SI-BONE, Inc. (NASDAQ:SIBN) Analysts at Truist Securiti issued their FY2023 earnings estimates for SI-BONE in a report issued on Tuesday, December 21st. Truist Securiti analyst D. Rescott expects that the company will earn ($1.11) per share for the year. SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, November 8th. The company reported []
SI-BONE (NASDAQ:SIBN) PT Lowered to $30.00
07:30am, Thursday, 23'rd Dec 2021 Dakota Financial News
SI-BONE (NASDAQ:SIBN) had its price objective cut by investment analysts at Truist Securities from $35.00 to $30.00 in a report issued on Tuesday, Analyst Price Targets reports. The brokerage presently has a buy rating on the stock. Truist Securities price objective indicates a potential upside of 41.24% from the companys previous close. A number of []
SI-BONE (NASDAQ:SIBN) Given Buy Rating at Needham & Company LLC
08:06am, Tuesday, 14'th Dec 2021 ETF Daily News
Needham & Company LLC reiterated their buy rating on shares of SI-BONE (NASDAQ:SIBN) in a research note issued to investors on Monday, Analyst Price Targets reports. The brokerage currently has a $32.00 price target on the stock. A number of other research analysts have also recently issued reports on the stock. Truist Securities decreased their […] The post SI-BONE (NASDAQ:SIBN) Given Buy Rating at Needham & Company LLC appeared first on ETF Daily News .
